Universal Vision Biotechnology Co., Ltd. (TPEX:3218)
Taiwan · Delayed Price · Currency is TWD 129.50
-2.50 (-1.89%)
Apr 20, 2026, 12:19 PM CST
TPEX:3218 Revenue
In the year 2025, Universal Vision Biotechnology had annual revenue of 4.20B TWD, down -0.57%. Universal Vision Biotechnology had revenue of 1.03B in the quarter ending December 31, 2025, a decrease of -0.48%.
Revenue
4.20B
Revenue Growth
-0.57%
P/S Ratio
2.66
Revenue / Employee
10.48M
Employees
401
Market Cap
11.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.20B | -24.22M | -0.57% |
| Dec 31, 2024 | 4.23B | 146.05M | 3.58% |
| Dec 31, 2023 | 4.08B | 588.20M | 16.83% |
| Dec 31, 2022 | 3.49B | 862.26M | 32.76% |
| Dec 31, 2021 | 2.63B | 578.66M | 28.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 20.51B |
| PharmaEssentia | 15.63B |
| Standard Chemical & Pharmaceutical | 7.02B |
| TaiDoc Technology | 4.20B |
| Vizionfocus | 3.49B |
| Foresee Pharmaceuticals | 431.27M |
| Tanvex BioPharma | 400.97M |
| Caliway Biopharmaceuticals | 38.04M |